Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
Andrea DeCensi(Memorial Sloan Kettering Cancer Center), Bernardo Bonanni(European Institute of Oncology), Matteo Puntoni(University of Parma), Marilena Petrera(Ente Ospedaliero Ospedali Galliera), Davide Serrano(European Institute of Oncology), Daniela Branchi(Ente Ospedaliero Ospedali Galliera), Matteo Lazzeroni(European Institute of Oncology), Franca Avino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marcella Gulisano(Azienda Industriali Municipali di Vicenza (Italy)), C. Taverniti(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Tania Buttiron Webber(Ente Ospedaliero Ospedali Galliera), Fabio Falcini(Centro di Riferimento Oncologico), Maria Grazia Pacquola(Ospedale Sant Antonio), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Aliana Guerrieri‐Gonzaga(European Institute of Oncology), Luca Boni(Ospedale Policlinico San Martino), Anna Cariello(Azienda Unità Sanitaria Locale Della Romagna), Maria Digennaro, Silvia Caviglia(Ente Ospedaliero Ospedali Galliera), Graziella Pinotti(Medica (Italy)), Sara Campora(Ente Ospedaliero Ospedali Galliera)
Cited by 218
Related Papers
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer
|Nature Medicine|2019|1.4k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k